Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine

M. J. Hepburn, M. G. Kortepeter, P. R. Pittman, E. F. Boudreau, J. A. Mangiafico, P. A. Buck, S. L. Norris, E. L. Anderson

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

A retrospective review was conducted of yellow fever vaccination among laboratory workers receiving annual serologic assessment to determine the initial and long-term response after boosting. Patients were divided into three groups based on pre-vaccination serology: Group 1, 1:10; Group 2, 1:20-1:40 and Group 3, >1:40. The percent with ≥four-fold increase in titers after booster vaccination were: 78% (646/829, Group 1), 65% (79/121, Group 2) and 10% (8/79, Group 3) (p < 0.0001). The median times to titer failure (<1:40) were 798 days (Group 1), 3340 days (Group 2) and 7709 days (Group 3) (p < 0.0001). Pre-vaccination serology influenced the initial and long-term response to yellow fever booster vaccination.

Original languageEnglish (US)
Pages (from-to)2843-2849
Number of pages7
JournalVaccine
Volume24
Issue number15
DOIs
StatePublished - Apr 5 2006

Fingerprint

Yellow Fever Vaccine
Yellow fever virus
Neutralizing Antibodies
neutralizing antibodies
Antibody Formation
Vaccination
vaccination
vaccines
Yellow Fever
Serology
secondary immunization
serology

Keywords

  • Booster
  • Neutralizing antibody
  • Yellow fever vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Hepburn, M. J., Kortepeter, M. G., Pittman, P. R., Boudreau, E. F., Mangiafico, J. A., Buck, P. A., ... Anderson, E. L. (2006). Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine. Vaccine, 24(15), 2843-2849. https://doi.org/10.1016/j.vaccine.2005.12.055

Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine. / Hepburn, M. J.; Kortepeter, M. G.; Pittman, P. R.; Boudreau, E. F.; Mangiafico, J. A.; Buck, P. A.; Norris, S. L.; Anderson, E. L.

In: Vaccine, Vol. 24, No. 15, 05.04.2006, p. 2843-2849.

Research output: Contribution to journalArticle

Hepburn, MJ, Kortepeter, MG, Pittman, PR, Boudreau, EF, Mangiafico, JA, Buck, PA, Norris, SL & Anderson, EL 2006, 'Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine', Vaccine, vol. 24, no. 15, pp. 2843-2849. https://doi.org/10.1016/j.vaccine.2005.12.055
Hepburn, M. J. ; Kortepeter, M. G. ; Pittman, P. R. ; Boudreau, E. F. ; Mangiafico, J. A. ; Buck, P. A. ; Norris, S. L. ; Anderson, E. L. / Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine. In: Vaccine. 2006 ; Vol. 24, No. 15. pp. 2843-2849.
@article{25efe14b74c04466875d8a1d3cf270c4,
title = "Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine",
abstract = "A retrospective review was conducted of yellow fever vaccination among laboratory workers receiving annual serologic assessment to determine the initial and long-term response after boosting. Patients were divided into three groups based on pre-vaccination serology: Group 1, 1:10; Group 2, 1:20-1:40 and Group 3, >1:40. The percent with ≥four-fold increase in titers after booster vaccination were: 78{\%} (646/829, Group 1), 65{\%} (79/121, Group 2) and 10{\%} (8/79, Group 3) (p < 0.0001). The median times to titer failure (<1:40) were 798 days (Group 1), 3340 days (Group 2) and 7709 days (Group 3) (p < 0.0001). Pre-vaccination serology influenced the initial and long-term response to yellow fever booster vaccination.",
keywords = "Booster, Neutralizing antibody, Yellow fever vaccine",
author = "Hepburn, {M. J.} and Kortepeter, {M. G.} and Pittman, {P. R.} and Boudreau, {E. F.} and Mangiafico, {J. A.} and Buck, {P. A.} and Norris, {S. L.} and Anderson, {E. L.}",
year = "2006",
month = "4",
day = "5",
doi = "10.1016/j.vaccine.2005.12.055",
language = "English (US)",
volume = "24",
pages = "2843--2849",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "15",

}

TY - JOUR

T1 - Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine

AU - Hepburn, M. J.

AU - Kortepeter, M. G.

AU - Pittman, P. R.

AU - Boudreau, E. F.

AU - Mangiafico, J. A.

AU - Buck, P. A.

AU - Norris, S. L.

AU - Anderson, E. L.

PY - 2006/4/5

Y1 - 2006/4/5

N2 - A retrospective review was conducted of yellow fever vaccination among laboratory workers receiving annual serologic assessment to determine the initial and long-term response after boosting. Patients were divided into three groups based on pre-vaccination serology: Group 1, 1:10; Group 2, 1:20-1:40 and Group 3, >1:40. The percent with ≥four-fold increase in titers after booster vaccination were: 78% (646/829, Group 1), 65% (79/121, Group 2) and 10% (8/79, Group 3) (p < 0.0001). The median times to titer failure (<1:40) were 798 days (Group 1), 3340 days (Group 2) and 7709 days (Group 3) (p < 0.0001). Pre-vaccination serology influenced the initial and long-term response to yellow fever booster vaccination.

AB - A retrospective review was conducted of yellow fever vaccination among laboratory workers receiving annual serologic assessment to determine the initial and long-term response after boosting. Patients were divided into three groups based on pre-vaccination serology: Group 1, 1:10; Group 2, 1:20-1:40 and Group 3, >1:40. The percent with ≥four-fold increase in titers after booster vaccination were: 78% (646/829, Group 1), 65% (79/121, Group 2) and 10% (8/79, Group 3) (p < 0.0001). The median times to titer failure (<1:40) were 798 days (Group 1), 3340 days (Group 2) and 7709 days (Group 3) (p < 0.0001). Pre-vaccination serology influenced the initial and long-term response to yellow fever booster vaccination.

KW - Booster

KW - Neutralizing antibody

KW - Yellow fever vaccine

UR - http://www.scopus.com/inward/record.url?scp=33644923779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644923779&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2005.12.055

DO - 10.1016/j.vaccine.2005.12.055

M3 - Article

C2 - 16494976

AN - SCOPUS:33644923779

VL - 24

SP - 2843

EP - 2849

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 15

ER -